Wall Street cheers after the company announced a surprise change in the corner office. Here's what investors need to know.
The health savings account provider finished its fiscal year with triple-digit profit growth, and it plans to bump up its spending rate.
Shares plunge after the company reports fourth-quarter results. Here's what investors need to know.
Find out why our Motley Fool contributors called out these three businesses as top opportunities right now.
Traders cheer the release of better-than-expected quarterly results and upbeat guidance.
News that an insider is rapidly adding to his position has the stock heading higher.
Shares of the software-as-a-service provider swoon in response to mixed quarterly results. Here are the key details for investors.
The liquid biopsy leader continues to expand at a rapid pace, and management expects more of the same in 2019.
Shares soar after the company reports strong fourth-quarter results and calls for more of the same in 2019.
Shares are jumping in response to upbeat earnings. Here are the must-know details for investors.
Traders cheered after some positive regulatory news emerged.
These cash-flow monsters are trading on the cheap. Which is the better bet for new money today?
These three healthcare gems have the full attention of our team of experts.
Shares tumbled after the company reported fourth-quarter results. Do the numbers justify the huge market reaction?
The diabetes-focused darling has been a monster winner. Is it too late to get in?
The identity-governance leader reports strong revenue and profit growth to cap off 2018.
The niche software provider posts revenue growth of 33% and is spending lavishly to expand its horizons.
Shares tumble after management reveals that an SEC inquiry is going to cause a delay in the filing of its annual 10-K report. Here's what investors need to know.
Shares soar after the company crushes expectations and raises guidance. Here's what investors need to know.
Both are fine businesses, but Veeva's future looks incredibly bright.